MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

Biotechnology

Healthcare
$53.42 -1.54%

-$0.64 today

Market cap
$2.65B
Beta
0.75
P/E (TTM)
-22.0
EPS (TTM)
-$1.86
52W Low $9.43High $45.85

Volume 0.73M

Average 0.65M

MBX Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

MBX Biosciences, Inc. Common StockNASDAQ: MBX

Capital Expenditures · Q3 FY2026 · quarter ended Sep 2026

Capital expenditures growth accelerates

Q3 FY2026 capital expenditures of $1.19M (cash outflow) rose 198.5% year over year, ahead of the +170.5% change in trailing-twelve-month capital expenditures. Sequentially, it rose 32.2% from the prior quarter. Over 3 fiscal years it compounded at +63.5% a year.

Context

  • Capital expenditures grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +198.5% holds above the trailing-twelve-month pace of +170.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$1.19M+32.2% QoQ
Last fiscal yearDec 2025
-$1.93M+120.7% YoY
LTMSep 2026
-$3.32M+170.5% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+198.5%——
1 year+120.7%——
3-year CAGR+63.5%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(1.93M) USD
Year-over-year change
-120.7%

Capital Expenditures vs competitors

How MBX compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +170.5% is the 3rd highest of 5, against a peer median of +155.2%.
  • Over three fiscal years its annual growth of +63.5% compares with a peer median of -17.5%.
MBX Competitors
Capital Expenditures for MBX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ASNDAscendis Pharma A/SLTM Sep 2026€17M EUR+210.4%-17.5%1.4%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$3.32M USD+170.5%+63.5%—
KLRAKailera Therapeutics, Inc.FY2025$2.09M USD———
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026$1.45M USD—-39.4%0.5%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$1.3M USD+81.3%+9.9%0.4%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$192.68K USD+1114.8%+57.4%—
ALTAltimmune, Inc.LTM Mar 2026$32K USD—-55.6%88.9%
VKTXViking Therapeutics, Inc.LTM Jun 2026$0 USD———
BMEABiomea Fusion, Inc.LTM Mar 2026$0 USD+100.0%——
Peer median (excluding MBX) —+155.2%-17.5%1.0%

Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.14M)(32.56M)(61.92M)(86.97M)
Depreciation & Amortization56K157K244K248K
Deferred Income Tax0000
Stock-Based Compensation306K2.04M5.22M8.68M
Change in Working Capital1.29M(735K)4.6M1.58M
Accounts Receivables0000
Inventory0000
Accounts Payables671K412K3.93M(2.46M)
Other Working Capital619K(1.15M)670K4.03M
Other Non-Cash Items1.36M(880K)(2.82M)(3.48M)
Operating Cash Flow(23.12M)(31.98M)(54.68M)(79.95M)
Capital Expenditures(441K)(129K)(874K)(1.93M)
Acquisitions (Net)0000
Purchases of Investments(20.22M)(63.8M)(239.47M)(358.15M)
Sales of Investments9.25M33M79.75M267.87M
Other Investing Activities0008.5M
Investing Cash Flow(11.41M)(30.93M)(160.6M)(83.71M)
Debt Repayment10M000
Common Stock Issued30K739K174.54M189.59M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(428K)(30K)(3.94M)0
Financing Cash Flow46.06M69.22M234.1M189.59M
Effect of Forex Changes0000
Net Change in Cash11.53M6.31M18.83M25.94M
Free Cash Flow(23.56M)(32.11M)(55.56M)(81.88M)

MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

Intrinsic Alpha fair value

Locked

Current Price

$53.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.